Constipation News and Research

Latest Constipation News and Research

Laboratorios Grifols, Cadence announce new supply agreement for OFIRMEV

Cadence Pharmaceuticals, Inc., a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply of commercial quantities of OFIRMEV (acetaminophen) injection in flexible plastic bags.

6 Mar 2013

Mirabegron reduces frequency of incontinence episodes in phase III trial

In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group.

5 Mar 2013

High-level results from AstraZeneca’s naloxegol Phase III trial on opioid-induced constipation

AstraZeneca today announced high-level results from KODIAC-08, an open-label, randomised, 52-week, long-term safety trial of naloxegol versus usual care (UC) in patients with non-cancer related pain and opioid-induced constipation (OIC). UC was defined as the investigator's choice of an existing laxative treatment regimen for OIC.

26 Feb 2013

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

23 Feb 2013

Physiotherapy aids defecation in constipated children

Physiotherapy may be an effective complementary therapy to laxatives for treating constipation in children, research indicates.

20 Feb 2013

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant.

16 Feb 2013

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today the U.S. commercial launch of UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

14 Feb 2013

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

10 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva Pharmaceutical Industries Ltd. announced today enrollment of the first patient in the MODERATO study - a Phase IV clinical study designed to evaluate the effect of AZILECT (rasagiline tablets) on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).

6 Feb 2013

Orphan, St George's sign licensing agreement to develop new therapies for metabolic disorders

St George's, University of London has signed an exclusive worldwide licensing agreement with rare-disease research-and-development firm Orphan Technologies Ltd to develop new therapies for deadly metabolic disorders.

5 Feb 2013

Risk factors identified for renal abnormality in vesicoureteral reflux

Researchers have identified the main risk factors for renal functional abnormalities in children with high-grade vesicoureteral reflux.

4 Feb 2013

GENIEUR teams aim to understand causes and treatment of irritable bowel syndrome

Europe-wide network GENIEUR including researchers from Sahlgrenska Academy, University of Gothenburg, Sweden, and Karolinska Institutet, Sweden, launch program for understanding the causes and improving the diagnosis and treatment of irritable bowel syndrome

29 Jan 2013

Merck receives FDA approval for Oxytrol to treat overactive bladder in women

The U.S. Food and Drug Administration today approved Oxytrol for Women, the first over-the-counter treatment for overactive bladder in women ages 18 years and older.

28 Jan 2013

Efficacy of docusate called into question

Docusate does not significantly improve the management of constipation in hospice patients, show the results of a randomized, placebo-controlled trial.

25 Jan 2013

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC).

23 Jan 2013

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.

23 Jan 2013

Constipation News and Research

Latest Constipation News and Research

Laboratorios Grifols, Cadence announce new supply agreement for OFIRMEV

Mirabegron reduces frequency of incontinence episodes in phase III trial

High-level results from AstraZeneca’s naloxegol Phase III trial on opioid-induced constipation

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

Physiotherapy aids defecation in constipated children

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Orphan, St George's sign licensing agreement to develop new therapies for metabolic disorders

Risk factors identified for renal abnormality in vesicoureteral reflux

GENIEUR teams aim to understand causes and treatment of irritable bowel syndrome

Merck receives FDA approval for Oxytrol to treat overactive bladder in women

Efficacy of docusate called into question

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

People with early Parkinson's frequently experience many non-motor symptoms

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Constipation News and Research

Latest Constipation News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in